Samsung Biologics/Kurma Partners manufacturing partnership

Share
Samsung Biologics and Kurma Partners announce strategic partnership
Samsung Biologics and Kurma Partners announce strategic partnership to develop and manufacture biologics for customisable CMC services

Announced by Samsung Biologics and Kurma Partners, the two organisations has established a strategic partnership to develop and manufacture biologics for Kurma Partners’ portfolio companies. 

“We are very excited to partner with Samsung Biologics, a world-leading CDMO with capabilities of highest industry standards. This will greatly benefit our portfolio of Kurma Biofunds and Kurma Growth Opportunities Fund in advancing large molecule biologics from discovery to the market.” said Daniel Parera, M.D., Partner at Kurma Partners. 

What does this mean for Samsung Biologics and Kurma Partners?

Signing a multi-year agreement, Samsung Biologics will provide customisable chemistry, manufacturing, and control (CMC) development services for Kurma Partners’ portfolio companies. 

The agreement will help to:

  • Streamline the gene to the Investigational New Drug (IND) process
  • De-risk uncertainties in CMC
  • Accelerate the lead candidate selection through entry into first-in-human studies with seamless transitions

The portfolio companies will also be able to leverage Samsung Biologics’ state-of-the-art facilities, proprietary technology platforms, and CMC-related expertise.

“As we look to further expand our business opportunities globally, we are pleased to collaborate with Kurma Partners to support the growth of pioneering biotech companies. With our in-depth knowledge of effective scale-up strategy and a diverse portfolio of proprietary platform technologies, we are looking forward to providing robust CMC solutions to reduce uncertainties, ensure regulatory compliance, and ultimately maximize manufacturing efficiency for our clients,” said John Rim, President and CEO of Samsung Biologics.

Investing in emerging biotechs

This latest agreement with Kurma Partners reflects Samsung Biologics’ commitment to supporting emerging biotech companies with drug development and manufacturing, as well as further increasing its business presence in its focus sectors and markets.

*************************************************

Check out our free upcoming virtual event, Manufacturing LIVE, 6th December 2023.

For more insights into Manufacturing - check out the latest edition of Manufacturing Magazine and be sure to follow us on LinkedIn & Twitter.

Other magazines that may be of interest - Healthcare Digital

*********************************************

BizClik is a global provider of B2B digital media platforms that cover 'Executive Communities' for CEO's, CFO's, CMO's, Sustainability Leaders, Procurement & Supply Chain Leaders, Technology & AI Leaders, Cyber Leaders, FinTech & InsurTech Leaders as well as covering industries such as Manufacturing, Mining, Energy, EV, Construction, Healthcare + Food & Drink.

BizClik, based in London, Dubai & New York offers services such as Content Creation, Advertising & Sponsorship Solutions, Webinars & Events.

Share

Featured Articles

Tata & JLR: Supercharging Next Gen Automotive Connectivity

With the Tata Communications MOVE platform, JLR is ensuring electric fleet connectivity, driving the future of software-defined automotive manufacturing

FUJIFILM Diosynth Biotechnologies Expands in Denmark

The life science company FUJIFILM Diosynth Biotechnologies is investing in its Hillerød site to drive the development & advancement of Danish life science

Reviewing Trump's First Term to Prepare for the Second

With Donald Trump returning to the White House, we reflect on the impact of the manufacturing policies, rules and tariffs imposed during his first term

Amazon Delivers One Billion Packages via Electric Vehicle

Sustainability & ESG

Rolls-Royce Invests Millions to Expand Goodwood Facility

Production & Operations

Manufacturing Unwrapped: Manufacturing Leader Jeff Winter

Digital Factory